John Carreyrou Orden de los libros (cronológico)

Spannend wie ein Thriller – der vielfach preisgekrönte New-York-Times-Bestseller jetzt als Taschenbuch Elizabeth Holmes, die Gründerin von Theranos, galt lange als der weibliche Steve Jobs. Das 19-jährige Start-up-Wunderkind versprach, mit ihrer Firma die Medizinindustrie zu revolutionieren. Ein einziger Tropfen Blut sollte reichen, um Diagnosen zu erstellen und Therapien zu steuern – eine Riesenhoffnung für Millionen Menschen und ein extrem lukratives Geschäft. Namhafte Investoren steckten Milliarden in das junge Unternehmen. Es gab nur ein einziges Problem: Die Technologie hat nie funktioniert. Pulitzer-Preisträger John Carreyrou kam dem gigantischen Betrug auf die Spur und erzählt in seinem preisgekrönten Buch die packende Geschichte seiner Enthüllung. Mit einem neuen Kapitel zum Prozess gegen Elizabeth Holmes.

The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.